Skip to main content

Advertisement

SpringerLink
Log in

Fall in Ki67 Index After Short-Term Preoperative Letrozole: a Gateway to Assess the Response in Hormone-Positive Early Breast Cancers

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Endocrine treatment for breast cancer acts largely by inhibiting tumor cell proliferation. The study aimed to explore the fall in proliferative marker Ki67 in patients receiving preoperative endocrine therapy and the factors associated with it. A prospective series of hormone receptor-positive postmenopausal women with early N0/N1 breast cancer were enrolled. Patients were requested to take letrozole OD while they await surgery. The fall in Ki67 after the endocrine therapy was defined as the percentage of the difference between the pre-and postoperative Ki67 value with the preoperative Ki67. Sixty cases matched the criteria of which 41 (68.3%) of women showed a good response to preoperative letrozole (fall in Ki67 > 50%; p-value < 0.001). The average mean fall in Ki67 was 57.083 ± 37.97. Postoperative Ki67 after the therapy was less than 10% in 39 (65%) patients. Ten patients (16.6%) had a low Ki67 index at baseline, which continued to remain low after preoperative endocrine therapy. The duration of the therapy did not affect the percentage of Ki67 fall in our study. Short-term changes in the Ki67 index in the neoadjuvant settings may predict outcomes during adjuvant use of the same treatment. Proliferation index on residual tumor holds prognostic importance, and our results reflect that greater attention should be given to the percentage of reduction of Ki67, rather than focusing purely on a fixed value. This could help predict patients who respond well to endocrine therapy, while those who respond poorly may require further adjuvant treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. World Health Organization. Breast cancer [Internet].2021 cited 2022 May 2. Available from https://www.who.int/news-room/fact-sheets/detail/breast-cancer

  2. Arthur LM, Turnbull AK, Khan LR, Dixon JM (2017) Pre-operative endocrine therapy. Curr Breast Cancer Rep 9:202–209. https://doi.org/10.1007/s12609-017-0255-6

    Article  PubMed  PubMed Central  Google Scholar 

  3. Zhang J, Yang C, Lei C, Zhang Y, Ji F, Gao H et al (2021) Survival outcomes after breast-conserving therapy compared with mastectomy for patients with early-stage metaplastic breast cancer: a population-based study of 2412 patients. Breast 58:10–17. https://doi.org/10.1016/j.breast.2021.03.010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Freelander A, Brown LJ, Parker A, Segara D, Portman N, Lau B, Lim E (2021) Molecular bomarkers for contemporary therapies in hormone receptor-positive breast cancer. Genes 12:285. https://doi.org/10.3390/genes12020285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chien TJ (2021) A review of the endocrine resistance in hormone-positive breast cancer. Am J Cancer Res 11:3813–3831

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Schiavon G, Tonini G (2010) Hormone-biological therapy in breast cancer: preclinical evidence, clinical studies and future directions. Curr Cancer Drug Targets 10:3–18. https://doi.org/10.2174/156800910790980278

    Article  CAS  PubMed  Google Scholar 

  7. Elmi A, Mcdonald ES, Mankoff D (2018) Imaging tumour proliferation in breast cancer: current update on predictive imaging biomarkers. PET clinics 13:445–457. https://doi.org/10.1016/j.cpet.2018.02.007

    Article  PubMed  PubMed Central  Google Scholar 

  8. Beelen K, Zwart W, Linn S (2012) Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol 9:529–541. https://doi.org/10.1038/nrclinonc.2012.121

    Article  CAS  PubMed  Google Scholar 

  9. Sun X, Kaufman PD (2018) Ki-67: more than a proliferation marker. Chromosoma 127:175–186. https://doi.org/10.1007/s00412-018-0659-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Li LT, Jiang G, Chen Q, Zheng JN (2015) Ki67 is a promising molecular target in the diagnosis of cancer. Mol Med Rep 11:1566–1572. https://doi.org/10.3892/mmr.2014.2914

    Article  CAS  PubMed  Google Scholar 

  11. Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ (2021) Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel) 13:4455. https://doi.org/10.3390/cancers13174455

    Article  CAS  PubMed  Google Scholar 

  12. Suman VJ, Ellis MJ, Ma CX (2015) The ALTERNATE trial: assessing a biomarker-driven strategy for the treatment of postmenopausal women with ER+/Her2- invasive breast cancer. Chin Clin Oncol 4:34. https://doi.org/10.3978/j.issn.2304-3865.2015.09.01

    Article  PubMed  PubMed Central  Google Scholar 

  13. Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C et al (2020) Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomized, phase 3 trial. Lancet Oncol 21:1443–1454. https://doi.org/10.1016/S1470-2045(20)30458-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Salvo EM, Ramirez AO, Cueto J, Law EH, Situ A, Cameron C, Samjoo IA (2021) Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Breast (Edinburgh, Scotland) 57:5–17. https://doi.org/10.1016/j.breast.2021.02.009

    Article  PubMed  Google Scholar 

  15. Boyaci C, Sun W, Robertson S, Acs B, Hartman J (2021) Independent clinical validation of the automated Ki67 scoring guideline from the International Ki67 in Breast Cancer Working Group. Biomolecules 11:1612. https://doi.org/10.3390/biom11111612

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ianza A, Giudici F, Pinello C, Corona S P, Strina C, Bernocchi O et al (2020) ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 42 https://doi.org/10.1177/1010428320925301

  17. Madani SH, Payandeh M, Sadeghi M, Motamed H, Sadeghi E (2016) The correlation between Ki-67 with other prognostic factors in breast cancer: a study in Iranian patients. Indian J Med Pediatr Oncol: Off J Indian Soc Med Paediatr Oncol 37:95–99. https://doi.org/10.4103/0971-5851.180136

    Article  Google Scholar 

  18. Cohen AL, Factor RE, Mooney K, Salama ME, Wade M, Serpico V et al (2017) POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. Breast 31:219–223. https://doi.org/10.1016/j.breast.2016.11.016

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Center, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India

    Dhanya Mary Louis & M. P. Narmadha

  2. Department of Breast Oncology, Amrita Institute of Medical Sciences and Research Center, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India

    Dehannathparambil Kottarathil Vijaykumar & Lakshmi Malavika Nair

  3. Department of Pathology, Amrita Institute of Medical Sciences and Research Center, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India

    Archana George Vallonthaiel & Jyotsna Yesodharan

  4. Department of Biostatistics, Amrita School of Medicine, Amrita Institute of Medical Sciences and Research Center, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India

    Renjitha Bhaskaran

Authors
  1. Dhanya Mary Louis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dehannathparambil Kottarathil Vijaykumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lakshmi Malavika Nair
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. P. Narmadha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Archana George Vallonthaiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jyotsna Yesodharan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Renjitha Bhaskaran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lakshmi Malavika Nair.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Louis, D.M., Vijaykumar, D.K., Nair, L.M. et al. Fall in Ki67 Index After Short-Term Preoperative Letrozole: a Gateway to Assess the Response in Hormone-Positive Early Breast Cancers. Indian J Surg Oncol 14, 208–214 (2023). https://doi.org/10.1007/s13193-022-01665-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-022-01665-w

Keywords

Search

Navigation